Breast Cancer Treatment Denied by Insurance: How to Appeal

A breast cancer diagnosis is devastating enough without the added burden of an insurance denial. Yet for tens of thousands of patients each year, that is exactly what happens. Whether the insurer is refusing to cover Herceptin, blocking a Kadcyla regimen, denying BRCA genetic testing, or second-guessing the surgical approach your oncologist recommended, these denials are not final. They are bureaucratic decisions that can and frequently should be overturned.

Why Breast Cancer Denials Happen

Insurers deny breast cancer claims for several overlapping reasons, most of which have more to do with cost management than clinical judgment.

HER2-targeted therapies (Herceptin, Perjeta, Kadcyla): Trastuzumab (Herceptin), pertuzumab (Perjeta), and ado-trastuzumab emtansine (Kadcyla/T-DM1) are FDA-approved for HER2-positive breast cancer at specific stages and lines of therapy. Insurers will frequently demand documentation of HER2 overexpression via IHC 3+ or FISH testing, Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization for each cycle, and evidence of prior treatment failure before approving a subsequent-line agent. Step therapy requirements — demanding you fail a cheaper drug first — are increasingly common and often clinically inappropriate.

BRCA1/2 genetic testing: The ACA mandates that insurers cover BRCA testing at no cost-sharing for individuals who meet USPSTF high-risk criteria. Despite this, many patients receive denials citing incorrect risk stratification, out-of-network lab processing, or "investigational" language for expanded panel testing. If your family history meets NCCN criteria for hereditary breast and ovarian cancer (HBOC) syndrome, a denial of genetic testing is almost certainly challengeable.

Lumpectomy vs. mastectomy: The Women's Health and Cancer Rights Act (WHCRA) of 1998 requires that group health plans covering mastectomy also cover reconstruction and symmetry procedures. However, some insurers attempt to influence surgical decisions by making mastectomy harder to authorize than lumpectomy, particularly when the treating surgeon recommends bilateral prophylactic mastectomy based on genetic risk or multifocal disease. Denials framing this as "elective" are legally suspect.

Neoadjuvant and adjuvant chemotherapy regimens: Denials of standard regimens like AC-T (doxorubicin, cyclophosphamide, paclitaxel) or dose-dense scheduling based on "not medically necessary" are common. These regimens are supported by NCCN Category 1 evidence and ASCO guidelines.

Common Denial Language and What It Actually Means

• "Not medically necessary" — The insurer's medical reviewer disagrees with your oncologist. This is the most commonly reversed denial on appeal.
• "Investigational or experimental" — Often applied to newer targeted agents even when FDA-approved. Check the approval date and indication carefully.
• "Step therapy required" — You must fail a prior treatment before approval. In many states, step therapy override laws protect oncology patients.
• "Out-of-network" — When in-network breast cancer specialists are unavailable, out-of-network necessity exceptions often apply.

Your Legal Protections

The ACA prohibits lifetime and annual dollar limits on essential health benefits, which include cancer treatment. The WHCRA protects reconstruction rights. The federal Mental Health Parity and Addiction Equity Act, while not directly applicable here, established a precedent that medical conditions cannot be arbitrarily limited.

Under ERISA (for employer-sponsored plans) and state insurance law (for individual and fully insured plans), you have the right to:

1. A full written explanation of any denial with the specific clinical criteria used
2. An internal appeal reviewed by a board-certified oncologist, not a general internist
3. An independent External Independent Review: Complete Guide" class="auto-link">external review if internal appeal fails

Many states — including California, New York, Illinois, and Texas — have enacted step therapy override laws specifically protecting cancer patients from being forced through clinically inappropriate sequences of treatment.

How to Build Your Appeal

Your appeal needs to be clinical and specific. Gather the following before filing:

• Your complete pathology report confirming diagnosis, stage, hormone receptor status, HER2 status, and Ki-67
• Peer-reviewed literature and NCCN guidelines supporting your recommended treatment
• A detailed letter of medical necessity from your oncologist explaining why the specific regimen is required and why alternatives are inferior or inappropriate
• Documentation of any prior treatments and their outcomes
• The insurer's clinical coverage criteria for the denied service (obtain via formal request)

A strong appeal frames the denial as inconsistent with the insurer's own coverage policy and with recognized oncology standards. If your oncologist is at an NCI-designated cancer center, include that institutional protocol documentation.

Fight Back With ClaimBack

ClaimBack helps breast cancer patients build medically grounded, legally informed appeals that get results. Our platform walks you through each step — from gathering the right documentation to crafting a compelling letter that insurers cannot easily dismiss.

Start your appeal at ClaimBack

Don't let a bureaucratic denial interrupt your treatment plan. The law is on your side, your oncologist is on your side, and ClaimBack is on your side.

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs. External Insurance Appeals